{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:24:10Z","timestamp":1785929050250,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s10147-024-02573-5","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T15:14:31Z","timestamp":1718723671000},"page":"1311-1325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-7356","authenticated-orcid":false,"given":"Makito","family":"Miyake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniaki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanosuke","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumisato","family":"Maesaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimi","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Mieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Ohmori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Tomizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunta","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Morizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Torimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the Nara Urological Research and Treatment Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"2573_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"2573_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/jjco\/hyx017","volume":"47","author":"T Matsuda","year":"2017","unstructured":"Matsuda T, Okuyama A (2017) Incidence rate for bladder cancer in Japanese in Japan and in the United States from the cancer incidence in five continents. Jpn J Clin Oncol 47:284\u2013285","journal-title":"Jpn J Clin Oncol"},{"key":"2573_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/jjco\/hyad170","volume":"54","author":"M Miyake","year":"2024","unstructured":"Miyake M, Nishimura N, Oda Y et al (2024) Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort. Jpn J Clin Oncol 54:329\u2013338","journal-title":"Jpn J Clin Oncol"},{"key":"2573_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.471","author":"P Barthelemy","year":"2023","unstructured":"Barthelemy P, Loriot Y, Voog E et al (2023) Full analysis from AVENANCE: a real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC). J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.471","journal-title":"J Clin Oncol"},{"key":"2573_CR5","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383:1218\u20131230","journal-title":"N Engl J Med"},{"key":"2573_CR6","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015\u20131026","journal-title":"N Engl J Med"},{"key":"2573_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carri\u00f3n A et al (2024) European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 Guidelines. Eur Urol 85:17\u201331","journal-title":"Eur Urol"},{"key":"2573_CR8","doi-asserted-by":"publisher","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","volume":"20","author":"TW Flaig","year":"2022","unstructured":"Flaig TW, Spiess PE, Abern M et al (2022) NCCN Guidelines\u00ae insights: bladder cancer, Version 2.2022. J Natl Compr Canc Netw 20:866\u2013878","journal-title":"J Natl Compr Canc Netw"},{"key":"2573_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2023.03.030","volume":"84","author":"P Grivas","year":"2023","unstructured":"Grivas P, Park SH, Voog E et al (2023) Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 84:95\u2013108","journal-title":"Eur Urol"},{"key":"2573_CR10","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1200\/JCO.19.03091","volume":"38","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Mortazavi A, Milowsky MI et al (2020) Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. J Clin Oncol 38:1797\u20131806","journal-title":"J Clin Oncol"},{"key":"2573_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2288-11-40","volume":"11","author":"A Vellinga","year":"2011","unstructured":"Vellinga A, Cormican M, Hanahoe B et al (2011) Opt-out as an acceptable method of obtaining consent in medical research: a short report. BMC Med Res Methodol 11:40","journal-title":"BMC Med Res Methodol"},{"key":"2573_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/jjco\/hyac186","volume":"53","author":"M Miyake","year":"2023","unstructured":"Miyake M, Shimizu T, Oda Y et al (2023) Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study. Jpn J Clin Oncol 53:253\u2013262","journal-title":"Jpn J Clin Oncol"},{"key":"2573_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","volume":"25","author":"C Pfister","year":"2024","unstructured":"Pfister C, Gravis G, Flechon A et al (2024) Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol 25:255\u2013264","journal-title":"Lancet Oncol"},{"key":"2573_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"2573_CR15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.4081\/oncol.2020.490","volume":"14","author":"GL Banna","year":"2020","unstructured":"Banna GL, Cantale O, Bersanelli M et al (2020) Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm. Oncol Rev 14:490","journal-title":"Oncol Rev"},{"key":"2573_CR16","doi-asserted-by":"publisher","first-page":"175883591880415","DOI":"10.1177\/1758835918804151","volume":"10","author":"N Mu\u00f1oz-Unceta","year":"2018","unstructured":"Mu\u00f1oz-Unceta N, Burgue\u00f1o I, Jim\u00e9nez E et al (2018) Durvalumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 10:1758835918804151","journal-title":"Ther Adv Med Oncol"},{"key":"2573_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.09.004","volume":"144","author":"E Rofi","year":"2019","unstructured":"Rofi E, Del Re M, Arrigoni E et al (2019) Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Crit Rev Oncol\/Hematol 144:102812","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"2573_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(23)00540-5","volume":"25","author":"E Grande","year":"2024","unstructured":"Grande E, Arranz J\u00c1, De Santis M et al (2024) Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol 25:29\u201345","journal-title":"Lancet Oncol"},{"key":"2573_CR19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M et al (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22:931\u2013945","journal-title":"Lancet Oncol"},{"key":"2573_CR20","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T et al (2023) Nivolumab plus Gemcitabine-Cisplatin in advanced urothelial carcinoma. N Engl J Med 389:1778\u20131789","journal-title":"N Engl J Med"},{"key":"2573_CR21","doi-asserted-by":"publisher","first-page":"196.e1","DOI":"10.1016\/j.clgc.2021.11.006","volume":"20","author":"M Miyake","year":"2022","unstructured":"Miyake M, Shimizu T, Nishimura N et al (2022) Response to pembrolizumab after dose-reduced cisplatin plus gemcitabine chemotherapy is inferior to that after carboplatin plus gemcitabine chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma. Clin Genitourin Cancer 20:196.e1-196.e9","journal-title":"Clin Genitourin Cancer"},{"key":"2573_CR22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1111\/iju.14686","volume":"28","author":"M Kato","year":"2021","unstructured":"Kato M, Kobayashi T, Matsui Y et al (2021) Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab. Int J Urol 28:1261\u20131267","journal-title":"Int J Urol"},{"key":"2573_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9A KO et al (2017) Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 17:97\u2013111","journal-title":"Nat Rev Immunol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02573-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02573-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02573-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T09:14:40Z","timestamp":1724663680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02573-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2573"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02573-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"16 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K Fujimoto received honoraria from Pfizer Inc., Merck Biopharma Co., Ltd, MSD K.K., Ono pharmaceutical co. Ltd and Astellas Pharma Inc.; received research funding from Pfizer Inc., Ltd, MSD K.K., Ono pharmaceutical co. Ltd and Astellas Pharma Inc.; served in a consulting or advisory role for Pfizer Inc. and Ono pharmaceutical co. Ltd. M Miyake receives honoraria from Pfizer Inc., Merck Biopharma Co., Ltd, MSD K.K., Ono pharmaceutical Co., Ltd., and Astellas Pharma Inc.; served in a consulting or advisory role for Pfizer Inc., Astellas Pharma Inc., Merck Biopharma Co., Ltd, and MSD K.K. Other authors disclose no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}